OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation

by NASDAQ Market News December 3, 2020

NASDAQ Market News
Click here to email author

New data supports development of colchicine for the prevention of acute respiratory distress syndrome

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Ads